News

Fortis Therapeutics, a UCSF Founded Startup, Closes $40 Million Series A Financing

March 29, 2021
Fortis Therapeutics, an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing.  “PCF is pleased that the 2017 funding to UCSF for their research on CD46 has been leveraged by Fortis for a...

Immunai Acquires UCSF Startup Dropprint Genomics

March 26, 2021
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. The Dropprint team co-founders Meena Subramaniam, PhD, and Rachel Gate, PhD, have also joined the Machine Learning and Computational...

NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

March 19, 2021
NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million.  MORE

Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for New Prostate Cancer Therapy

March 18, 2021
Founded in 2018 and based on technology developed at the University of California San Francisco, Alessa Therapeutics is developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease. And have announced the enrollment of the first patient in the...

UCSF Technology Sings at San Francisco Opera

March 11, 2021
In a strange marriage of arts and science, The San Francisco Opera costume department teamed up with doctors from UCSF to create a mask that will allow the company's singers to safely rehearse together -- while greatly diminishing the chances of spreading COVID-19. WATCH

Sana Announces Closing of Initial Public Offering

March 02, 2021
Sana Biotechnology, a UCSF startup company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $675.6 million. All of the shares of common stock were...

Weill Neurohub Joins Forces with Genentech and Roche to Advance Neuroscience Research

By Pete Farley and Robert Sanders on February 25, 2021
UC San Francisco and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS),...

‘AutoImmunoprofiler’ Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases

By Alan Toth on February 22, 2021
UCSF Partners With Eli Lilly to Better Understand Underlying Drivers of Autoimmunity and Accelerate the Development of Better Therapies.  MORE

Calico and AbbVie Take UCSF Technology Into Clinical Trials

February 03, 2021
Calico Life Sciences and AbbVie announced clinical-stage programs in two areas – immuno-oncology and neurodegeneration, currently in Phase I studies. The lead Calico neurodegeneration molecule is based on novel technology licensed from the lab of Peter Walter, Professor of Biochemistry and...

Sana Biotechnology Files for IPO

By Megan Campbell on January 20, 2021
UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. MORE

Pages